Acta Neuropsychiatrica
December 2010
Gislaine T Rezin, Cinara L Gonçalves, Juliana F Daufenbach et al.
Rezin GT, Gonçalves CL, Daufenbach JF, Carvalho-Silva M, Borges LS, Vieira JS, Hermani FV, Comim CM, Quevedo J, Streck EL. Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress. Recently, we reported that mitochondrial respiratory chain complexes I, III and IV were inhibited in the cerebral cortex and cerebellum of rats...
Revista Brasileira de Psiquiatria
September 2009
Lara C Assis, Gislaine T Rezin, Clarissa M Comim et al.
Clinical findings suggest that ketamine may be used for the treatment of major depression. The present study aimed to compare behavioral effects and brain Creatine kinase activity in specific brain regions after administration of ketamine and imipramine in rats. Rats were acutely given ketamine or imipramine and antidepressant-like activity was assessed by the forced swimming test; Creatine...
Brain Research Bulletin
August 14, 2009
Gislaine T Rezin, Cinara L Gonçalves, Juliana F Daufenbach et al.
Modulation and dysfunction of the glutamatergic system seems to be involved in depression. Recently a renewed interest in the glutamatergic system as a treatment option for major depression emerged by the finding that the glutamate N-methyl-D-aspartate (NMDA) antagonist ketamine leads to a rapid improvement of depressive symptoms. Several works support the hypothesis that metabolism impairment...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 30, 2009
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety disorders and major depression. Additionally, studies have shown that ketamine induces antidepressant effects in humans as well as in rodents subjected to animal models of depression. In this context, the present...
Basic & Clinical Pharmacology & Toxicology
December 2008
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
A growing body of evidence has pointed to the blockade of the N-methyl-d-aspartate (NMDA) receptor signaling as a potential therapeutic target for the treatment of major depression. The present study was aimed to evaluate behavioural and molecular effects of the chronic treatment with ketamine and imipramine in rats. To this aim, rats were 14 days treated once a day with ketamine (5, 10 and 15...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 1, 2008
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor. Clinical findings point to a rapid onset of action for ketamine on the treatment of major depression. Considering that classic antidepressants may take long-lasting time to exhibit their main therapeutic effects, the present study aims to compare the behavioral effects and the BDNF...